ClinicalTrials.gg
RecruitingNCT07082192Updated Sep 22, 2026

A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)

A Phase 2/3 interventional study of Test drug CB03-154 5mg group and Test drug CB03-154 10mg group in ALS (Amyotrophic Lateral Sclerosis), sponsored by Shanghai Zhimeng Biopharma, Inc.. Recruiting at 1 site in China. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2026-09-22.

Sponsored by Shanghai Zhimeng Biopharma, Inc. · Phase 2/3, Interventional, and Treatment

From the registry’s dates

  • Started Oct 2025; still recruiting 1 year later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2/3
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 55 studies in Amyotrophic Lateral Sclerosis with a site in China — 24 open to participants now, 29 under way, 1 of them phase 3. Amyotrophic Lateral Sclerosis · China.

Planned enrollment
3rd of 39
240 · median 24
Started
2025
with 8 others
Phase 2/3
2 of 55
1 open now
Primary completion
2027-09
later than 20 of 28 live
Registered
48th of 55
by date

Among the 55 studies in Amyotrophic Lateral Sclerosis with a site in China, this one is the 3rd largest by planned enrollment of the 39 interventional ones that give a count, is one of 9 that started in 2025, is one of 2 in phase 2/3, reaches primary completion later than 20 of the 28 other live ones, and was the 48th registered.

Amyotrophic Lateral Sclerosis

980 studies on the registry are indexed under Amyotrophic Lateral Sclerosis; 279 are open to participants now.

Browse Amyotrophic Lateral Sclerosis studies →

Open to participants now

24 of the 55 studies in Amyotrophic Lateral Sclerosis with a site in China are open now. Recruiting first, the newest first:

18 more — sign in →

All 24 open studies →

A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →

Who these studies take

Of the 193 Amyotrophic Lateral Sclerosis studies recruiting now, 118 (61%) set no upper age limit and 23 (12%) stop at 75 or younger; 15 take children under 18; 55 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 55 studies in Amyotrophic Lateral Sclerosis with a site in China, or all of them as a file.
02

Study summary

The goal of this clinical trial is to learn if drug CB03-154 works to treat ALS in adults. It will also learn about the safety of drug CB03-154.

The main questions it aims to answer are:

  • Does drug CB03-154 have an effect on delaying disease progression, improving function, and prolonging survival in adult ALS patients?
  • What medical problems do patients have when taking drug CB03-154? Researchers will compare drug CB03-154 to a placebo (a look-alike substance that contains no drug) to see if drug CB03-154 works to treat ALS.

Participants (adult ALS patients) will:

  • Take drug CB03-154 or a placebo every day for 39 weeks (an additional 39 weeks would be required if entering the open-label extension phase).
  • Visit the clinic approximately every 2-3 months for checkups and tests, and there is also telephone follow-up in between.
  • Keep a diary of daily medication (CB03-154 or other concomitant medications), and if there are any unplanned medications, the reason (disease or symptoms) also need be recorded.
03

Conditions studied

  • ALS (Amyotrophic Lateral Sclerosis)
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Agree to follow the treatment plan and trial procedures of this study, and sign the written form.
  2. Male or female, aged 18 to 65 years, inclusive.
  3. The weight of subjects during the screening period must not be less than 45 kg, and the must not be less than 18 kg/m2.
  4. Diagnosed according to the Revised EI Escorial diagnostic criteria set by the World Federation of Neurology: definite ALS, probable ALS, lab supported probable ALS, or possible ALS.
  5. Less than or equal to 24 months since ALS symptom onset at Screening, and estimated survival time of ≥1 year as per the Investigator's judgement.
  6. Forced vital capacity (FVC) >80% of predicted value for gender, height, and age at Screening.
  7. Able to swallow oral medication (tablets) at Screening as judged by the investigator.
  8. For participants taking riluzole: Dose must be stable for at least 4 weeks prior to Screening and participant must be expected to remain on treatment for the duration of the trial. Participants receiving riluzole should maintain the same dose throughout the study.
  9. Currently not receiving edaravone treatment or is in the schedule of edaravone treatment cycle. Participants receiving edaravone treatment must complete at least one cycle of treatment before the screening visit and continue stable dose edaravone treatment throughout the study.
  10. Women of (WOCBP) must use an approved highly effective for at least one menstrual cycle before the first dose of the product and for at least 3 months after the last dose of the investigational product. Similarly, men must start using effective contraception before the first dose of the investigational product and continue for at least 3 months after the last dose of the investigational product, with no plans for procreation. Male participants cannot donate sperm for at least 3 months during the trial and after the last dose of the investigational product and female participants cannot donate or freeze eggs during the trial and for at least 3 months after the last dose of the investigational product.

Exclusion criteria

Exclusion Criteria:

  1. Significant cognitive impairment, mental disorders (such as schizophrenia, bipolar disorder), other neurodegenerative diseases (such as Parkinson's disease, Alzheimer's disease, frontotemporal dementia, etc.), substance abuse or other causes leading to neuromuscular weakness (such as myasthenia gravis), or other conditions that may interfere with the participants' participation in clinical study or, in the investigator's judgment, may interfere with outcome assessment or affect the completion of the trial.
  2. Serum (AST), alanine aminotransferase (ALT), or >2.0× at screening.
  3. Estimated \<59 mL/min/1.73m2 at Screening (using the formula to calculate eGFR: eGFR (mL/min/1.73m2) = Ccr × 0.84 × 1.73 / BSA; Ccr (mL/min) = [(140 - age) × weight (kg)] / [72 × Scr (mg/dL)], females multiply the result by 0.85, and Scr is the serum creatinine; BSA (m2) = 0.007184 × weight (kg)\^0.425 × height (cm)\^0.725).
  4. D-dimer>2.0× upper limit of normal or venous ultrasound of the lower limbs shows deep vein thrombosis at screening or a history of venous thrombosis.
  5. Assistance with ventilation support or tracheostomy or tube feeding status or having a central venous catheter is required at screening.
  6. A history of unexplained syncope, family history of syncope, or a history of convulsions or epilepsy (excluding the history of febrile seizures in childhood), or unstable medical condition, serious heart issues (e.g., corrected interval: males >450ms, females >470ms, torsades de pointes, class 3 or higher heart failure, myocardial infarction or unstable angina within 6 months prior to screening), lung, liver, kidney diseases, or tumors, or other diseases or medical history (excluding ALS), participation in this study could threaten the safety of the participants.
  7. Current clinically significant urinary retention, or current use of medications for urinary retention, or clinically significant abnormalities in residual urinary bladder ultrasound at screening.
  8. Clinically significant ophthalmological abnormalities found in visual acuity examination (best corrected visual acuity), fundus photography, OCT examination, etc. during screening period, or clinically significant fundus lesions or retinopathy known or recorded in medical history.
  9. surface antigen (HBsAg) positive, or antibody (HCVAb) positive and hepatitis C virus ribonucleic acid (HCV-RNA) test higher than the lower limit of detection, or antibody (HIVAb) positive, or Treponema pallidum (TP) antibody positive (also judged as active infection by the investigator) at screening.
  10. Severe infections (e.g., infectious pneumonia, sepsis) within 4 weeks prior to screening, or infections requiring hospitalization or intravenous administration of antibiotics, antiviral drugs, or antifungal medications, or chronic active bacterial infections (e.g., tuberculosis) deemed by the investigator to be unsuitable for participation in this trial.
  11. Received Tofersen treatment before screening.
  12. Significant risk of suicidality based on the Investigator's opinion or with an answer of "yes" on either item 4 or item 5 of the Suicidal Ideation Section of the Columbia Suicide Severity Rating Scale (C-SSRS) or any answer of "yes" within the Suicidal Behavior Section of the C SSRS within the 6 months before Screening.
  13. Exposure to any other medicinal product or product within 4 weeks or 5 half-lives of the investigational product (whichever is longer) prior to Screening; or exposure to monoclonal antibody drug within 6 months prior to Screening (or if the at the time of screening has not reached more than 3 months), or had received cell therapy or gene therapy at any time in the past.
  14. Treatment with strong inducers or strong inhibitors prior to screening, and washout time of more than 5 half-lives of the drug was not reached before enrollment。
  15. Pregnant, currently breastfeeding women or women with a positive pregnancy test at screening.
  16. Known history of allergy to any component of the investigational medicinal product.
  17. History of drug abuse within 12 months of Screening.
  18. Anything else that, in the opinion of the Investigator, would place the participant at increased risk or preclude the participant's full compliance with or completion of the trial.
Terms in these criteria, in plain language(18)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

GFR and eGFR (kidney filtering)

GFR (glomerular filtration rate) is how much blood the kidneys filter each minute. It is usually estimated from a blood test — eGFR, by formulas such as CKD-EPI or MDRD — and some studies ask for it to be measured directly instead. Usually given in mL/min/1.73 m².

Check the method, the units and the minimum the study states. A value of 90 or above is in the normal-or-high range, but kidney damage can show in other tests too.

Creatinine clearance (CrCl)

How quickly the kidneys clear creatinine, a waste product, from the blood. A study may estimate it from a blood test with age, weight and sex (often by the Cockcroft–Gault formula), or measure it using blood and urine collected over a set time. Given in mL/min; higher is better.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Quadruple (Participant, Care provider, Investigator, Outcomes assessor)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    CB03-154 5mg

    Participants will receive CB03-154 5mg and Placebo 10mg orally once daily for 39 weeks.

    Drug: Test drug CB03-154 5mg group

  • Experimental
    CB03-154 10mg

    Participants will receive CB03-154 10mg and Placebo 5mg orally once daily for 39 weeks.

    Drug: Test drug CB03-154 10mg group

  • Experimental
    CB03-154 15mg

    Participants will receive CB03-154 15mg orally once daily for 39 weeks.

    Drug: Test drug CB03-154 15mg group

  • Placebo comparator
    Placebo 15mg

    Participants will receive Placebo 15mg orally once daily for 39 weeks.

    Drug: Placebo Group

Interventions

  • DrugTest drug CB03-154 5mg group

    One CB03-154 tablet (5mg/tablet) once daily.

  • DrugTest drug CB03-154 10mg group

    Two CB03-154 tablets (5mg/tablet) once daily.

  • DrugTest drug CB03-154 15mg group

    Three CB03-154 tablets (5mg/tablet) once daily.

  • DrugPlacebo Group

    Three Placebo tablets once daily.

06

What researchers measure

Primary outcomes

  1. Changes from Baseline to Week 39 in ALS Functional Rating Scale-Revised (ALSFRS-R).(Part A) Changes from Baseline to Week 78 in ALS Functional Rating Scale-Revised (ALSFRS-R).(Part B)

    Time frame: From baseline to the entire period of double-blind period, assessed up to 39 weeks. (Part A) From baseline to the entire period of open-label extension, assessed up to 78 weeks. (Part B)

Secondary outcomes

  1. A joint rank analysis of function (Functional Rating Scale-Revised , ALSFRS-R) and survival(ALS/SURV)score at Week 39.(Part A) A joint rank analysis of function (Functional Rating Scale-Revised , ALSFRS-R) and survival(ALS/SURV)score at Week 78.(Part B)

    Time frame: From baseline to the entire period of double-blind period, assessed up to 39 weeks. (Part A) From baseline to the entire period of open-label extension, assessed up to 78 weeks. (Part B)

  2. Change from Baseline and Slope of decline from Baseline in the Functional Rating Scale-Revised (ALSFRS-R) score at Weeks 8, 16, 28, 39, 51, 63 and 78.

    Time frame: From baseline to the entire period of double-blind period, assessed up to 39 weeks. (Part A) From baseline to the entire period of open-label extension, assessed up to 78 weeks. (Part B)

  3. Change from Baseline and slope of decline in the Rasch Overall ALS Disability Scale (ROADS) score at Weeks 8, 16, 28, 39, 51, 63, and 78.

    Time frame: From baseline to the entire period of double-blind period, assessed up to 39 weeks. (Part A) From baseline to the entire period of open-label extension, assessed up to 78 weeks. (Part B)

  4. Time from baseline to the earliest occurrence of 1 of the following events: first use of Permanent Assisted Ventilation (PAV) for >22 hours per day for >7 consecutive days OR death.

    Time frame: From baseline to the entire period of double-blind period, assessed up to 39 weeks. (Part A) From baseline to the entire period of open-label extension, assessed up to 78 weeks. (Part B)

  5. Time from baseline to death.

    Time frame: From baseline to the entire period of double-blind period, assessed up to 39 weeks.

  6. Change from Baseline in Forced Vital Capacity (FVC) at Weeks 8, 16, 28, 39, 51, 63 and 78.

    Time frame: From baseline to the entire period of double-blind period, assessed up to 39 weeks. (Part A) From baseline to the entire period of open-label extension, assessed up to 78 weeks. (Part B)

  7. Change from Baseline in the Hamilton Depression Rating Scale, 17 item (HAMD-17) score at Weeks 8, 16, 28, 39, 51, 63, and 78.

    Time frame: From baseline to the entire period of double-blind period, assessed up to 39 weeks. (Part A) From baseline to the entire period of open-label extension, assessed up to 78 weeks. (Part B)

  8. Change from Baseline in the Amyotrophic Lateral Sclerosis Assessment Questionnaire (ALSAQ-40) score at Weeks 8, 16, 28, 39, 51, 63 and 78.

    Time frame: From baseline to the entire period of double-blind period, assessed up to 39 weeks. (Part A) From baseline to the entire period of open-label extension, assessed up to 78 weeks. (Part B)

  9. Change from Baseline on concentration of plasma Neurofilament Light Chain (NfL) at Weeks 8, 16, 28, 39, 51, 63 and 78.

    Time frame: From baseline to the entire period of double-blind period, assessed up to 39 weeks. (Part A) From baseline to the entire period of open-label extension, assessed up to 78 weeks. (Part B)

07

Study locations

1 of 1 sites recruiting
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Oct 2025 (actual). Primary completion is estimated for Sep 2027, 23 months after the start.

Of 22 phase 2/3 interventional studies under Amyotrophic Lateral Sclerosis, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 109. This study's planned 23 months is close to that.

How these figures are worked out, and which studies are left out of them.

Registered
Jul 11, 2025
First posted
Jul 24, 2025
StartActual
Oct 30, 2025
Primary completionEst.
Sep 30, 2027
CompletionEst.
Oct 2027
Last update
Sep 22, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 22, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT07082192
Lead sponsor
Shanghai Zhimeng Biopharma, Inc.
Responsible party
Sponsor
First posted
Jul 24, 2025
Start date
Oct 30, 2025
Primary completion
Sep 30, 2027 (estimated)
Completion
Oct 2027 (estimated)
Last update
Sep 22, 2026

Study contacts

Dongsheng Fan, MD,PhD
Contact
dsfan@aliyun.com
+86 10 82265694

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion